Literature DB >> 20231237

Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association.

A Singanayagam1, J D Chalmers, A T Hill.   

Abstract

Inhaled corticosteroids (ICS) are commonly used in the treatment of chronic obstructive pulmonary disease. Recent large prospective trials have reported an increased incidence of pneumonia in patients treated with ICS. Despite this, the link between ICS and pneumonia remains controversial. In this review, pro and con arguments for the association between ICS and increased pneumonia risk are discussed, drawing on evidence from experimental and clinical research.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20231237     DOI： 10.1093/qjmed/hcq023

Source DB:  PubMed          Journal:  QJM        ISSN： 1460-2393


  15 in total

1.  Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.

Authors:  Mario Cazzola; Paola Rogliani; Maria Gabriella Matera
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

2.  Glucocorticoids relieve collectin-driven suppression of apoptotic cell uptake in murine alveolar macrophages through downregulation of SIRPα.

Authors:  Alexandra L McCubbrey; Joanne Sonstein; Theresa M Ames; Christine M Freeman; Jeffrey L Curtis
Journal:  J Immunol       Date:  2012-05-21       Impact factor: 5.422

Review 3.  Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review.

Authors:  Hernan Iannella; Carlos Luna; Grant Waterer
Journal:  Ther Adv Respir Dis       Date:  2016-02-18       Impact factor: 4.031

4.  Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function.

Authors:  Valerie R Stolberg; Alexandra L McCubbrey; Christine M Freeman; Jeanette P Brown; Sean W Crudgington; Sophina H Taitano; Bridget L Saxton; Peter Mancuso; Jeffrey L Curtis
Journal:  J Immunol       Date:  2015-05-18       Impact factor: 5.422

5.  Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: How Significant is the Risk of Pneumonia and Should It Impact Use of Inhaled Corticosteroids?

Authors:  Rodrigo Cavallazzi; Sonal Singh
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

6.  Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance.

Authors:  Oriol Sibila; Elena Laserna; Eric M Mortensen; Antonio Anzueto; Marcos I Restrepo
Journal:  Respir Care       Date:  2013-01-23       Impact factor: 2.258

Review 7.  Efferocytosis and lung disease.

Authors:  Alexandra L McCubbrey; Jeffrey L Curtis
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

Review 8.  Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.

Authors:  Kayleigh M Kew; Alieksei Seniukovich
Journal:  Cochrane Database Syst Rev       Date:  2014-03-10

9.  Haemophilus influenzae responds to glucocorticoids used in asthma therapy by modulation of biofilm formation and antibiotic resistance.

Authors:  Chris S Earl; Teh Wooi Keong; Shi-qi An; Sarah Murdoch; Yvonne McCarthy; Junkal Garmendia; Joseph Ward; J Maxwell Dow; Liang Yang; George A O'Toole; Robert P Ryan
Journal:  EMBO Mol Med       Date:  2015-08       Impact factor: 12.137

10.  Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia.

Authors:  Jordi Almirall; Ignasi Bolíbar; Mateu Serra-Prat; Elisabet Palomera; Jordi Roig; Imma Hospital; Eugenia Carandell; Mercè Agustí; Pilar Ayuso; Andreu Estela; Antoni Torres
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.